CRS

Business Context and Reporting Period

Company: Carpenter Technology Corporation (CRS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2026 (Fiscal Year 2026)
Business Overview: A producer and distributor of premium specialty alloys, including titanium, powder metals, stainless steels, and tool steels, serving aerospace, defense, medical, energy, and industrial markets. The company operates two segments: Specialty Alloys Operations (SAO) and Performance Engineered Products (PEP).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 12% in Q3 and 7% in the nine-month period, driven by a 17% increase in Aerospace and Defense sales and a 49% increase in Energy sales. Medical sales declined 23% in Q3 due to supply chain inventory management.
• Margin Expansion: Operating margins improved significantly (23.0% in Q3 vs. 19.0% prior year) due to pricing realization, improved product mix, and operational efficiencies. Adjusted operating margin (excluding surcharges) reached 28.4% in Q3.
• Debt Restructuring: In November 2025, the company issued $700 million in 5.625% Senior Notes due 2034 to refinance existing debt. This resulted in a one-time debt extinguishment loss of $15.6 million in the nine-month period.
• Capital Allocation: The company repurchased $133.9 million of common stock in the nine-month period and paid $30.2 million in dividends. Capital expenditures increased to $157.6 million (9M) to fund a brownfield expansion project.
• Segment Performance: The SAO segment delivered record operating income of $208.0 million in Q3. The PEP segment saw a decline in sales and operating income, primarily due to lower Medical market demand.

Guidance, Outlook, and Risks

• Outlook: Management expects sustained growth driven by accelerating demand in the Aerospace and Defense sector, particularly for structural materials. The company is advancing long-term agreements to secure volume visibility.
• Capital Expenditures: Full-year fiscal 2026 capital expenditures are expected to be approximately $260.0 million, including the brownfield expansion.
• Tax Environment: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 includes changes to R&D deductions and bonus depreciation. Management does not expect a material impact on the effective tax rate but notes complexity in quantification.
• Risks:
  • Geopolitical: Monitoring conflicts involving the U.S., Israel, and Iran, and their impact on end-use markets.
  • Raw Materials: Volatility in raw material costs, though mitigated by surcharge mechanisms and commodity hedging.
  • Medical Market: Continued pressure from customers managing inventory levels closely.

Investor Verification Checklist

• Debt Refinancing Impact: Verify the long-term interest savings from the November 2025 refinancing against the $15.6 million one-time extinguishment cost.
• Medical Segment Recovery: Monitor the trajectory of the Medical end-use market, which declined significantly (23% in Q3), to assess if inventory destocking is complete.
• Surcharge Dependency: Review the "Adjusted" margins (excluding surcharges) to understand core profitability independent of raw material pass-throughs.
• Capital Expenditure Execution: Track progress on the $260 million FY2026 capex plan, specifically the brownfield expansion, to ensure it aligns with projected capacity growth.
• Share Repurchase Runway: Confirm remaining authorization ($164.2 million) and potential for future buybacks given strong free cash flow generation.